Pulmonx (LUNG) EBITDA (2019 - 2025)

Pulmonx (LUNG) has 7 years of EBITDA data on file, last reported at -$14.4 million in Q3 2025.

• EBITDA for Q3 2025 came in at -$14.4 million, down 5.68% year-over-year; the trailing twelve-month figure through Sep 2025 was -$57.0 million (down 0.94% YoY), and the FY2024 annual result was -$56.9 million, up 4.78% from the prior year.
• EBITDA climbed to -$14.4 million in Q3 2025 per LUNG's latest filing, from -$14.7 million in the prior quarter.
• Over five years, EBITDA peaked at -$10.1 million in Q3 2021 and troughed at -$16.1 million in Q1 2022.
• A 5-year average of -$14.1 million and a median of -$14.4 million in 2025 frame the typical range for EBITDA.
• The sharpest annual moves came in 2021 and 2024: EBITDA sank 164.33% in 2021, then grew 8.91% in 2024.
• A 5-year view of EBITDA shows it stood at -$12.8 million in 2021, then declined by 9.87% to -$14.1 million in 2022, then gained by 6.47% to -$13.2 million in 2023, then declined by 3.06% to -$13.6 million in 2024, then dropped by 5.58% to -$14.4 million in 2025.
• Business Quant data shows LUNG's EBITDA at -$14.4 million in Q3 2025, -$14.7 million in Q2 2025, and -$14.4 million in Q1 2025.